Ο ρόλος των γενόσημων φαρμάκων στα οικονομικά της υγείας
The role of generics in the health economy
View/ Open
Subject
Φαρμακευτικός κλάδος ; ΦάρμακαKeywords
Γενόσημα φάρμακα ; Πρωτότυπα φάρμακα ; Μελέτη βιοϊσοδυναμίας ; Τιμολόγηση φαρμάκων ; Πολιτική γενοσήμων ; Generics ; Branded drugs ; Bioequivalence study ; Pricing of generics drugs ; Policy of generics drugsAbstract
While the use of generics is known for many decades in Europe as well as in other countries, it is in the last recent years that generic drugs have been known in Greece. This paper studies the impact of generics in the Economy of Greece as well as of other countries. Factors influencing patients’ and health professionals’ attitude with regard to generics are also studied. Several measures have already been adopted by the Greek State to increase the use of generics in pharmaceutical industry. It is mentioned that the issue of generic drugs is of great importance not only in Greece but also in whole Europe. Generics policy constitutes the most significant section concerning generic drugs including the ability to control the cost of pharmaceutical care and the management of the opportunities that arise when the patent protection expires. Measures and instruments contributing to a successful generics policy vary from nation to nation. The generics policy in Greece emphasizes on solving outstanding institutional problems and reducing pharmaceutical cost. Nowadays, price control is the key on the way achieving these objectives. Current policy in generics is a result of memorandum obligations of our country. It is characterized by the cumulative and ineffective invasion of political measures applied in other countries trying to maximize the effect of the pharmaceutical cost reduction. Apart from the obvious benefits accompanying generics use, their penetration into the pharmaceutical market is of great general importance regarding the Economy including jobs creation, exports, taxation income and a larger pharmaceutical market as a result of the expiration of branded drugs patent.